Deals & Cases

Schellenberg Wittmer advised Santhera on the sale of its Raxone®/Idebenone business


Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici S.p.A. The transaction replaces the existing license agreement between the two companies entered into in 2019.

Under the terms of the acquisition agreement, Chiesi acquired all assets and certain liabilities related to idebenone in all indications worldwide, including Raxone in LHON, for which Chiesi already held exclusive license rights globally since 2019, except for North America and France. As consideration, Chiesi will assume the responsibility for the settlement agreed between Santhera and the French reimbursement authorities relating to Raxone in LHON amounting to approx. EUR 25,300,000.

The team of Schellenberg Wittmer consisted of Pascal Hubli (Corporate/M&A), Philipp Groz (IP/Life Sciences) as well as Elia Schunck (Corporate/M&A).


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.